Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. META

Go back to Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis
(NASDAQ: RARX) Delayed: 48.00 --0 (-0%)
Previous Close $48.00    52 Week High $14.86 
Open $2.00    52 Week Low $12.33 
Day High $48.00    P/E N/A 
Day Low $48.00    EPS $0.00 
Volume 10